MedTrace Logo

CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

NCT02629419 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-08-07

Study results available
· View outcomes & findings →

Summary

This is an open-label, dose-titration trial to study the efficacy, safety, and pharmacokinetics of oral cochleate amphotericin B (CAMB) in the treatment of mucocutaneous candidiasis infections in patients who are refractory or intolerant to standard non intravenous therapies.

Conditions

  • Candidiasis, Chronic Mucocutaneous

Interventions

DRUG

Amphotericin B

Oral lipid nanocrystal formulation of amphotericin B

Sponsors & Collaborators

  • Matinas BioPharma Nanotechnologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Alexandra Freeman, MD · National Institute of Allergy and Infectious Diseases (NIAID)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-27
Primary Completion
2021-11-09
Completion
2022-08-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02629419 on ClinicalTrials.gov